NVS - Novartis AG

NYSE - Nasdaq Real Time Price. Currency in USD
83.24
+0.85 (+1.03%)
As of 12:56PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close82.39
Open82.78
Bid83.22 x 800
Ask83.24 x 2200
Day's Range82.65 - 83.36
52 Week Range64.78 - 86.30
Volume1,428,672
Avg. Volume2,642,672
Market Cap194.316B
Beta (3Y Monthly)0.67
PE Ratio (TTM)15.78
EPS (TTM)5.27
Earnings DateN/A
Forward Dividend & Yield2.83 (3.45%)
Ex-Dividend Date2019-03-04
1y Target Est99.00
Trade prices are not sourced from all markets
  • Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO
    CNBC18 hours ago

    Fix 'distortions' in health care system ahead of slate of drug launches: Novartis CEO

    "I can't remember a time at Novartis where year after year after year we have these significant medicines getting launched," CEO Vasant Narasimhan says.

  • Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches
    CNBC Videos18 hours ago

    Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches

    "I can't remember a time at Novartis where year after year after year we have these significant medicines getting launched," CEO Vasant Narasimhan says.

  • Novartis CEO on single-payer health care: It is not the right move for America
    CNBC Videosyesterday

    Novartis CEO on single-payer health care: It is not the right move for America

    CNBC's Healthy Returns summit discusses what is shaping the future of health care innovation with investors and executives. CEO of Novartis Dr. Vasant Narasimhan joins CNBC's Jim Cramer at the summit to discuss the most pressing topics in the health care sector.

  • TheStreet.com3 hours ago

    Novartis Is a Difficult Stock to Trade or Own - Suggested Risk Point

    Narasimhan said the U.S. remains an ecosystem of incredible innovation and he's not advocating wholesale changes to the system but rather smart reform to balance the distortions. Novartis is leading the charge in Washington to help Congress and regulators begin thinking about these new treatments and new models. Turning to the business of NVS, Narasimhan noted that his company has 26 potential blockbuster treatments in its pipeline, but it is still committed to spending $9 billion on R&D. Let's review the charts and indicators this morning.

  • Benzinga5 hours ago

    The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive ...

  • Cramer Remix: The cannabis stocks I'm eyeing
    CNBC17 hours ago

    Cramer Remix: The cannabis stocks I'm eyeing

    Jim Cramer turns to the charts to reveal that cannabis companies like GW Pharmaceuticals and Village Farms could be good additions to your portfolio.

  • Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches
    CNBC19 hours ago

    Novartis CEO calls for fixing 'distortions' in health care system ahead of slate of drug launches

    "I can't remember a time at Novartis where year after year after year we have these significant medicines getting launched," CEO Vasant Narasimhan says.

  • These 3 Major Drug Manufacturers Are Strong Performers
    GuruFocus.comyesterday

    These 3 Major Drug Manufacturers Are Strong Performers

    Roche Holding AG (RHHBY) has climbed 2.4% over the last week, 0.5% over the past month, 5.7% so far this year, 17.6% over the last 52 weeks and 5.3% over the past three years through May 20. Warning! GuruFocus has detected 3 Warning Signs with RHHBY. Currently, the company is paying an annual dividend of $1.07 per common share, which, based on the closing share price on May 20, leads to a forward dividend yield of 3.27% versus the industry median of 1.66%.

  • Novartis CEO says cannabis isn't a focus despite Tilray partnership
    CNBCyesterday

    Novartis CEO says cannabis isn't a focus despite Tilray partnership

    Speaking with CNBC's Jim Cramer from the "Healthy Returns" conference in New York City, Novartis CEO Vas Narasimhan says cannabis is "not a focus" for the pharma company.

  • Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study
    Zacks2 days ago

    Adverum Up as FDA Lifts Hold on Cohort of Wet AMD Study

    Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.

  • Primary Drivers of the Chinese Economy
    Investopedia2 days ago

    Primary Drivers of the Chinese Economy

    Learn about the forces driving the Chinese economy and helping the country earn money. China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.

  • 3 Ways to Buy Into the Marijuana Boom Without the Risk
    InvestorPlace2 days ago

    3 Ways to Buy Into the Marijuana Boom Without the Risk

    [Editor's note: This story was previously published in April 2019. It has since been updated and republished.]Marijuana stocks are all the rage these days as legalized cannabis has hit the scene. Analysts now project that the market for both medical and recreational cannabis use will reach a staggering $200 billion in global sales in just five years. As a result, stocks in the sector have surged on the wave of optimism.The problem is, marijuana stocks aren't exactly a slam dunk.InvestorPlace - Stock Market News, Stock Advice & Trading TipsMany are fraught with some big-time risks, hefty volatility, zero profits, etc. At this point, many marijuana stocks are just speculative bets. They could pay off or they could crash and burn. But one thing many of the top cannabis stocks do have is partners. Specifically, major corporate partners that are as far from speculative plays as you can get.It's here that more conservative investors can cash in on the marijuana stock mania and benefit from everything it has to offer. Sure, these stocks won't rise as much as some of the pure marijuana stocks. But, you know what? They won't fall as much either and they'll still be able to reap potential billions in revenues derived from cannabis. * 7 High-Yield REITs to Buy (Even When the Market Tanks) With that, here are the three top partners of the marijuana stocks and why they are good stocks to buy. Constellation Brands (STZ)Source: Shutterstock Seemingly overnight, Constellation Brands (NYSE:STZ) become one of the biggest marijuana stocks out there. That's thanks to its big partnership with Canopy Growth (NYSE:CGC). For a cool $4 billion, STZ purchased a 38% stake in Canopy last year. The firm now owns warrants that would allow it own a majority stake in 2021.The end game for STZ is pretty simple. Marijuana would be a perfect "fourth leg of a stool" to the company's beer, wine, and spirits operations. Constellation owns over 100 world class beverage brands including Corona beer, Svedka Vodka, and Robert Mondavi wines. These are highly regulated consumer products. The end goal is for STZ to do the same with cannabis. That is, apply its vast branding knowledge and distribution network to get various pot products into the hands of the masses.Constellation has already started working with Canopy on cannabis-infused drinks. At the same time, it's looking to parlay is vast marketing knowledge into other cannabis areas such as edibles and other consumable products. These can and will all be major sources of revenues once the switch is flipped and full legalization happens.In the meantime, STZ is no slouch with regards to what it already generates money on and its recently undergone some moves to shore up its balance sheet and pay for CGC purchase. This allows it to be a safer play than any of the marijuana stocks. Novartis (NVS)Source: Shutterstock One of the main reasons why marijuana stocks have surged so far has been the growing use of medical marijuana and cannabis treatments. Demand in that area has already begun to surge, and it could grow further as doctors look for alternatives to addictive opioids for pain relief.International drug giant Novartis (NYSE:NVS) saw the writing on the wall and decided that it needed to get into the cannabis game. This prompted it to partner with major grower Tilray (NASDAQ:TLRY).That partnership allows for NVS division Sandoz to develop and distribute TLRY's medical marijuana in legal jurisdictions around the world. With the deal, Tilray is able to tap into Novartis' vast distribution network and will allow TLRY to help commercialize its non-smokable/noncombustible medical cannabis products. For NVS, it's able to collect fees and revenues from sales. Moreover, the deal allows it to co-brand some products to help enhance sales further.For both partners, the deal seems like a win-win. NVS gets its hands-on fast-growing medical marijuana, while Tilray can actually sell its products to more consumers. Given how good the deal is, both firms decided to expand more on those partnerships and look into developing new cannabis-related drugs. * 7 High-Yield REITs to Buy (Even When the Market Tanks) The win for investors by choosing NVS over TLRY is that you get the backing of one of the largest drug manufacturers on the planet. Altria (MO)Source: Peyri Herrera via Flickr (Modified)Big Tobacco has been eyeballing legalized cannabis sales for what seems like decades, so it's no surprise that cigarette-king Altria (NYSE:MO) would be looking at the marijuana stocks for a partnership. That came from a $1.8 billion investment in pot grower Cronos Group (NASDAQ:CRON). MO now has a 45% stake in the firm.Traditional cigarette sales continue to fall and MO has been looking for ways to expand its portfolio and reduce potential revenue loss. This helps explain its major purchase of vaping specialist Juul Labs. Its CRON buy helps expand on that vaping tech.Speculation has already begun that Altria could fill Juul Pods with CBD once pot is legal everywhere or add it to its other vaping/e-cigarette brands. Meanwhile, MO's huge production facilities could instantly be flipped towards smokable marijuana products. The deal also allows for CRON to co-develop new products that could be sold on Altria's large network. Together, it gives Altria an instant foothold in a growing business.And that's important for the firm. Potentially, it gives Big Tobacco a way to really reduce its multi-year declines. Last quarter again, Altria managed to miss analysts' consensus sales estimates.Meanwhile, investors buying MO over other marijuana stocks getsplenty of stability, profits and a hefty 5.93% dividend yield.Disclosure: At the time of writing, Aaron Levitt did not hold a position in any of the marijuana stocks mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post 3 Ways to Buy Into the Marijuana Boom Without the Risk appeared first on InvestorPlace.

  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacks2 days ago

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock
    InvestorPlace5 days ago

    Don’t Let the Great Q1 Numbers Fool You into Buying Tilray Stock

    After a revenue beat Tilray Inc (NASDAQ:TLRY) saw its stock jump 5% for the day. However, that optimism has faded rather quickly, and Tilray stock has not been able to capitalize on that momentum.Source: Shutterstock Unequivocally, it has been a wild ride for Tilray investors. Last fall, against a very frothy overall market and marijuana stocks going more mainstream, the stock price exceeded the $200 mark before getting cut down by three quarters, trading at less than $50 per share as of this writing. * 6 Chinese Stocks That Could Pop On a Trade Deal Still though, I remain cautious on Tilray stock. The company hit a major milestone by landing a partnership with Novartis AG (NYSE:NVS), the Swiss pharmaceutical company, late last year. That's certainly been a positive catalyst, but after all the hype, investors need to see meaningful progress toward a more profitable future.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tilray Stock Has a Mixed First QuarterA lot of the focus immediately after earnings was around revenues. TLRY delivered a massive 195 increase in year-over-year revenues. The legalization of marijuana use in Canada for adults last year in addition to hemp food sales from Tilray's acquisition of Manitoba Harvest were big drivers.Gross margins also saw a slight increase, but despite these positive signs, net losses for the quarter increased dramatically. Last quarter $5 million to $30 million most recently. For a growth company, it's not necessarily unexpected. Expansion costs money as companies need to lay the foundation for future endeavors, but the point is that it's naive to look only at the revenue beat and think TLRY stock is headed for the sky.Total kilogram equivalents sold did double to 3,012 kilograms, but compare that to fellow competitor Canopy Growth (NYSE:CGC) that sold 10,102 kilogram equivalents in the most recent quarter and has a higher pricing structure.TLRY is still doesn't have pricing figured out seeing as average net selling price per gram decreased over the prior year period. As the space gets more and more competitive, TLRY needs to optimize this quickly as increasing supply toward medical and consumer purposes will put pressure on prices. The trend is not going in the right direction. Tilray Stock Is OvervaluedUltimately, TLRY stock looks lofty in terms of valuation. This, of course, does not mean the stock cannot get more expensive from here, but it's not a screaming buy despite some decent first quarter numbers.Tilray's consensus forward P/E is the kind of number that makes you triple check because you don't think it can be right: 1,111x. Compare that 357x for CGC. It's a relative game with P/E ratios, so even though 357x may also sound extraordinarily rich, it goes to show that 1,111x is completely irrational.There is just so many ways for that multiple to get rerated downward, again and again. Final Note on Tilray StockThe first quarter earnings was a bit of a mixed bag. The market gave credit where it was due but no more than that, recognizing the weak points in the financials.Tilray has made progress on expansion via M&A, which may bolster future earnings, but only time will tell. There is a lot of success already built into the current valuation, meaning that TLRY can't miss a beat. As of this writing, Luce Emerson did not hold a position in any of the aforementioned securities. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy that Lost 10% Last Week * Top 7 Dow Jones Stocks of 2019 -- So Far * 5 Service Stocks That Can Win the Trade War -- According to Goldman Sachs Compare Brokers The post Don't Let the Great Q1 Numbers Fool You into Buying Tilray Stock appeared first on InvestorPlace.

  • CNBC5 days ago

    Commentary: Novartis CEO says gene therapies promise to upend US health system, pricing structure

    The current global health system treats chronic diseases with a pay-as-you-go model, spreading costs over months and years. It's unprepared to pay for a surge of new, single-treatment therapies with the potential to provide a lifetime of benefit.

  • CNBC5 days ago

    Commentary: Novartis CEO: Gene therapy offers hope of cures in one treatment, but US needs new pricing and payment model

    Advances in cell and gene therapies are beginning to yield powerful new treatments for some of the most devastating illnesses. This is a major breakthrough, but it will introduce new upfront cost challenges to our already stretched health-care system. Policymakers and companies must work together to solve these challenges so that patients can gain access to the tremendous benefit these therapies deliver.

  • Reuters5 days ago

    GSK and Novartis liniment marketing misled Australian consumers - court

    The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday. The court said the companies admitted marketing Voltaren Osteo Gel as a treatment for osteoarthritis-related pain when its ingredients were the same as a cheaper Voltaren product, Emulgel. Judge Robert Bromwich said in a written decision that it was part of a "deliberate and considered marketing strategy".

  • Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed
    InvestorPlace6 days ago

    Tilray Stock Is Red-Hot, But It’s Fundamentally Flawed

    Cannabis company Tilray (NASDAQ:TLRY) desperately needed a win with Tuesday's release of its first quarter of 2019 earnings report. Not only is Tilray stock down more than 38% since the end of March, the share price is only one-sixth of its peak value from September of last year.Source: Shutterstock It got the win. Although the net loss per share widened year-over-year, revenue almost tripled. The top line also topped analyst estimates.Perhaps the biggest driver behind Wednesday's initial gain, however, was the discussion of Tilray's growth prospects. Already partnering with beverage giant Anheuser Busch Inbev (NYSE:BUD) to create cannabis-infused drinks, Tilray stock has massive potential. Company CEO Brendan Kennedy fueled those fires, commenting during the conference call about being "inundated" with partnership requests from Fortune 500 companies.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Retirement Stocks That Won't Wilt in a Bear Market Still, significant challenges remain, spurring a sharp reversal of Wednesday's initial rally in the TLRY stock price. TLRY Earnings RecapTilray wasn't the only name to report last quarter's earnings on Tuesday. Aurora Cannabis (NYSE:ACB) did as well.Tilray was decidedly the better performer of the two, however. As evidence, Tilray stock gained nearly 5% on Tuesday and was up another couple of percentage points early on Wednesday. ACB stock rallied about as well as TLRY stock did on Tuesday but unwound those gains and more on Wednesday.The market celebrated Tilray's sales. The company's top line of $23.0 million, even adjusted downward to $21.5 million to account for excise taxes, still topped the consensus outlook of $20.16 million. The adjusted loss of 27 cents per share of TLRY stock, while much worse than the 7-cent loss per share in the year-ago quarter, essentially met analysts' consensus target.Gross margins improved sequentially, from 20% to 23%. However, they were well off the 50% level seen during Q1 2018, before Canada had legalized recreational marijuana.The volatile margins figure reflects investments made in cultivation facilities and accounting rules about inventory valuations. To meet demand, Tilray is buying marijuana from third-party suppliers. This costs the company more than it would to grow that supply itself. That third-party supply, though, may not be a high-quality leaf.Expenses related to the acquisitions of Manitoba Harvest also took a toll on profitability.When all was said and done though, investors couldn't get over the subtle but telling shift in selling prices. While sales volume more than doubled to 3,012 kilograms, the average selling price fell from $5.94 per gram a year ago to $5.60 per gram last quarter. That slide at least partially reflects the ongoing commoditization of marijuana. Unfortunately, this trend will continue to drive prices lower until only the cost-conscious, high-scale players are left. Perspective Required for TLRY StockTake last quarter's numbers for Tilray stock with a grain of salt, for better or worse. It, like all other marijuana stocks, represents a moving target for several reasons.One of them is the simple fact that the cannabis market in Canada is new. Prior to October, there was no legal adult-use revenue to report.The purchase of Manitoba Harvest also added food sales of $5.6 million to the mix, but only for part of the quarter. It's also arguable that Tilray may be able to better distribute Manitoba's goods better than Manitoba could on its own. If so, it could set the stage for tremendous growth going forward.One area where Tilray is lacking is its international exposure. Overseas sales only totaled $1.8 million last quarter. The right tweaks, however, could readily change that for the better.Still, Tilray boasts some of the primo deals with major names. Aside from the Anheuser Busch partnership, Tilray has inked a supply deal with pharmaceutical giant Novartis (NYSE:NVS). Both could be game-changers once their upsides are fully realized. But it could take several quarters for either large company to decide what they want with their cannabis journey.Selling more marijuana at ever-shrinking prices isn't necessarily a big step in the right direction.Whatever the case, Tilray's most immediate problem is clear. "Our growth internationally and in Canada continue to be limited by lack of supply that we expect to improve over time," explained Tilray Chief Financial Officer Mark Castaneda during the earnings conference call. The company believes it could take up to two more years before supply and demand find an equilibrium. It remains to be seen where the TRLY stock price will stabilize once that equilibrium is met. Looking Ahead for Tilray StockTLRY shares may have initially shot higher in response to first-quarter earnings, but the bounce appears almost pre-planned. It was poised to take shape no matter what due to the sheer severity of the selloff leading into Tuesday's news. Little revealed about the quarter implies much has actually changed since the end of Q4. Everything has just scaled up, including the loss, and the bears were relentless.Those same bears dug in again on Wednesday, recognizing that simply selling marijuana doesn't ensure meaningful or even modest profitability.That's also true of rival marijuana companies, by the way. The entire industry is spending huge sums of money to garner a piece of a market that may not justify the expenditures.Though he was speaking of the decision to establish more capacity rather than arrange for more cultivation, Kennedy's comment about believing "all the hype 18 months ago" rang out alarmingly. He essentially summarized the hype surrounding the cannabis market for the past year-and-a-half.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 10 Retirement Stocks That Won't Wilt in a Bear Market * 5 Consumer Stocks Ready to Push Higher * 3 of the Best ETFs to Buy for a Play on Gold Stocks Compare Brokers The post Tilray Stock Is Red-Hot, But It's Fundamentally Flawed appeared first on InvestorPlace.

  • MoneyShow6 days ago

    Three Conservative Ways to Play Cannabis

    Forget the marijuana stocks, as their partners are more of a sure thing, asserts Mark Leibovit, growth stock expert and editor of The VR Cannabis Letter.

  • Teva Hits Fibonacci Support on Concerns Over Lawsuit
    Investopedia7 days ago

    Teva Hits Fibonacci Support on Concerns Over Lawsuit

    Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.

  • The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
    Zacks7 days ago

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

    The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer

  • Reuters7 days ago

    Novartis gets approval to sell Kymriah in Japan for $306,000

    A Japanese government panel approved on Wednesday a price of 33.5 million yen ($305,800) for Novartis' cancer treatment Kymriah, allowing the Swiss drugmaker to press ahead with a campaign to kick-start sluggish sales of the treatment. The one-time, personalised therapy, which was approved in Japan in March, will be available in the country for young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL).

  • Ionis Pharmaceuticals Is 40% of the Way There
    Motley Fool8 days ago

    Ionis Pharmaceuticals Is 40% of the Way There

    A large licensing payment from one of the biotech's partners drives revenue growth.

  • Generic Drugmakers Face Antitrust Suit Alleging Price Fixing
    Zacks8 days ago

    Generic Drugmakers Face Antitrust Suit Alleging Price Fixing

    Shares of generic drugmakers decline on allegations of price fixing by 44 states.

  • Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
    Zacks8 days ago

    Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion

    Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.